Elanco Animal Health beats Q3 revenue, profit estimates; hikes FY forecast

Elanco Animal Health Incorporated

05/11/2025 11:34

Overview

Elanco Q3 revenue rises 10% yr/yr, surpassing analyst expectations

Adjusted EPS for Q3 beats consensus, increasing 46% yr/yr

Company raises full-year revenue and innovation targets, reflecting growth confidence

Outlook

Elanco raises full-year revenue guidance to $4,645 mln to $4,670 mln

Company increases 2025 innovation revenue target by $100 mln to $840 mln-$880 mln

Elanco improves year-end net leverage ratio target to 3.7x-3.8x

Result Drivers

NEW PRODUCTS - Credelio Quattro and Zenrelia drove significant growth in pet health revenue, contributing to a 10% increase

FARM ANIMAL SALES - Increased volumes in cattle and poultry, led by Experior, boosted farm animal revenue by 12%

INNOVATION FOCUS - Elanco raised its innovation revenue target, highlighting momentum for products like Credelio Quattro and Zenrelia

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$1.13 bln
$1.09 bln (11 Analysts)
Q3 Adjusted EPS
Beat
$0.19
$0.13 (12 Analysts)
Q3 EPS
-$0.07
Q3 Adjusted Net Income
Beat
$94 mln
$65.45 mln (11 Analysts)
Q3 Net Income
-$34 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Elanco Animal Health Inc is $23.00, about 2.2% above its November 4 closing price of $22.50

The stock recently traded at 23 times the next 12-month earnings vs. a P/E of 15 three months ago

Press Release: ID:nPn29B3PVa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)